Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab)

NCT01418430 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2011-08-22

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of the combination of CHOP plus daclizumab in patients with ATLL previously untreated with anthracycline based chemotherapy.

Conditions

  • HTLV-I Associated Adult T-cell Leukaemia/Lymphoma (ATLL)

Interventions

DRUG

CHOP-daclizumab

Sponsors & Collaborators

  • King's College Hospital NHS Trust

    lead OTHER

Study Design

Purpose
TREATMENT

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01418430 on ClinicalTrials.gov